| Document |
Document Title |
|
WO/2013/038430A1 |
Disclosed herein is 10-α/β-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R" are as defined herein in the specification. Th...
|
|
WO/2013/037566A1 |
The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory ...
|
|
WO/2013/034119A1 |
The invention relates to phenoxy derivatives having glycosidically bound sugar residues, to pharmaceutical compositions containing such compounds, to the uses of such compounds and compositions, and to methods for producing such compound...
|
|
WO/2013/022985A2 |
The present invention relates to compounds involved in nematode signaling.
|
|
WO/2013/022345A1 |
The invention relates to O-acylated O-alkylated monoglycosides, and to their use as plasticizing or coalescing agents for compositions comprising a thermoplastic polymer. The invention further relates to a method for preparing said O-acy...
|
|
WO/2013/020979A1 |
The present invention relates generally to catechin and epicatechin conjugates of formula (I). For example, a chemical synthesis process for the preparation of catechin and epi-catechin compounds, in particular of catechin and epi-catech...
|
|
WO/2013/019662A1 |
Provided herein are glycosidic aryl naphthalide lignans compounds, such as justiprocumin A isolated from the plant Justicia gendarussa Burm.f. (Acanthaceae), which are effective in the treatment of AIDS and HIV infections.
|
|
WO/2013/017254A1 |
The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap- ( 1→3 ) -β-D-Glcp- ( 1→4 ) - [a-L-R...
|
|
WO/2013/012737A1 |
This invention provides new active compounds for pharmaceutical use including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma,...
|
|
WO/2013/008062A1 |
The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a pyrene based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate ...
|
|
WO/2013/004086A1 |
Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated ...
|
|
WO/2013/002346A1 |
Provided are: a (meth) allylsilane compound that is chemically bonded to a variety of alcohol derivatives such as saccharides and other polyol derivatives, is a raw material used to cause a substrate to express functionality such as anti...
|
|
WO/2013/000275A1 |
Disclosed are compounds as shown as general formula (I), derivatives and uses thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c and X have the definition as same as the description.
|
|
WO/2012/175813A1 |
This invention relates to synthetic oligo- or multivalent beta- 1 - 2 - linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell -mediated immune responses.
|
|
WO/2012/173477A1 |
Title: Methods for chemical synthesis of biologically active compounds using supramolecular protective groups and novel compounds obtainable thereby. Abstract The invention relates to drug development and synthetic chemistry, in particul...
|
|
WO/2012/172566A2 |
The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the pr...
|
|
WO/2012/173942A2 |
Methods and materials for producing organic syringomycin, the methods include culturing a culture of Pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a...
|
|
WO/2012/167813A1 |
The present invention relates to a process, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, until a stationary growth phase is obtained, -cultivating said pre-cultivated cells in ...
|
|
WO/2012/167920A1 |
The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related inventio...
|
|
WO/2012/168325A1 |
The present invention relates to a process for selectively producing sophorolactone without use of organic solvent, comprising the steps of: -pre-cultivating cells of a Candida species capable of producing sophorolactone, in absence of a...
|
|
WO/2012/061662A9 |
Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells i...
|
|
WO/2012/164062A1 |
The invention relates to triterpenes and triterpene glycosides of the formula (I) and/or physiologically acceptable salts thereof, preferably naturally occurring triterpenes and triterpene glycosides from Mycetia balansae and/or physiolo...
|
|
WO/2012/163508A1 |
The invention relates to crystalline epirubicin hydrochloride and to a method for producing it. The method for producing crystalline epirubicin hydrochloride comprises the steps of (a) providing epirubicin hydrochloride, (b) preparing a ...
|
|
WO/2012/164074A1 |
Compounds of the formula (I) (I) wherein n is 0, 1 or 2, R1 is aryl, heteroaryl or heterocyclyl, and R2 and R3 are, independent of each other, hydrogen or a substituent as described in the specification, and one of RA, RB, RC and RD is P...
|
|
WO/2012/161559A2 |
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...
|
|
WO/2012/160337A1 |
Compounds which interact with HlsTONES Compounds of Formula I : • 4"'-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4'-Sulfo-Fu- cose [alpha]1-4-Glucuronic acid [beta]1-0-Methyl or • 4" "-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fu...
|
|
WO/2012/161250A1 |
Provided is an alpha-glucosidase which is easily obtainable and easily handled, and the enzyme activity of which is activated by an activator, and which effectively does not generate malto-oligosaccharides with a degree of polymerization...
|
|
WO/2012/155916A1 |
The present invention relates to the synthesis of the tetrasaccharide of formula (I) and novel intermediates used in the synthesis.
|
|
WO/2012/156273A1 |
A method for the manufacture an infant formula or an infant nutritional product comprising mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2 ...
|
|
WO/2012/146774A1 |
The present invention concerns a compound of formula (I) the salt, solvate, enantiomer, diastereoisomer and racemic mixture thereof for treating or preventing ischemia/reperfusion injury associated disorders during surgical operations or...
|
|
WO/2012/140596A1 |
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ph...
|
|
WO/2012/140576A1 |
A compound of the formula (I) wherein R1 is a group removable by hydrogenolysis,and wherein R2 is OH or R2 is -NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The c...
|
|
WO/2012/141228A1 |
Provided is a novel therapeutic means for Alzheimer's disease. A compound represented by general formula (I) [wherein Ar1 represents a 2-methoxy-4-(2-pyridylmethoxy)phenyl group or the like; and Ar2 represents a 1H-indole-6-yl group or t...
|
|
WO/2012/142615A2 |
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...
|
|
WO/2012/129651A1 |
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...
|
|
WO/2012/119846A1 |
The present invention relates to synthetic lipoteicoic acid (LTA) mimeticswhich are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.
|
|
WO/2012/121394A1 |
The present invention provides a substituted aromatic compound represented by general formula (I) [wherein A1, A2 and A3 independently represent an aryl group substituted by a hydrophilic group].
|
|
WO/2012/121862A2 |
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...
|
|
WO/2012/122282A1 |
A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impu...
|
|
WO/2012/116447A1 |
A combination of a bacterial endotoxin, in particular a lipopolysaccharide, and a lipoteichoic acid for treating or preventing a metabolic disorder or bacterial infection, or for improving milk energy efficiency in a subject. The combina...
|
|
WO/2012/113405A1 |
A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the m...
|
|
WO/2012/107204A1 |
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetness enhancer, to sweetener compositions comprising at least one sweetener and the compoun...
|
|
WO/2012/107205A1 |
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetener and/or a sweetness enhancer, to sweetener compositions comprising the compound of for...
|
|
WO/2012/104145A1 |
The present invention relates to an improved process for the preparation of an extract enriched in dihydrochalcones, and more specifically enriched in phlorizin, starting from a polyphenolic fraction originating from industrial apple pro...
|
|
WO/2012/101605A1 |
The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I) in which R1 represents an optionally substituted -O-alkyl group, R2 represents a hydroxyl group or an -O-alkyl group, R3, R5, R6, R7 and R...
|
|
WO/2012/007585A9 |
The invention relates to a method for purifying, separating and/or isolating an oligosaccharide of general formula 1 or a salt thereof (general formula 1) wherein R1 is fucosyl or H, R2 is fucosyl or H, R3 is selected from H, sialyl, N-a...
|
|
WO/2012/097876A1 |
A novel class of cell-penetrating enhancers with unusual chemical structure is herein disclosed. Said cell-penetrating enhancers are non-linear and non peptidic (guanidyl)-oligosaccharidic derivatives, which can be easily obtained accord...
|
|
WO/2012/099477A1 |
The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to ...
|
|
WO/2012/097454A1 |
This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof: wherein R1 to R4. R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said c...
|
|
WO/2012/099904A1 |
The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive a...
|
